News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ALK-Abello A/S Release: Positive Results From Pivotal Phase III Trial of New Allergy Immunotherapy Tablet Against House Dust Mite-Induced Allergic Asthma


7/11/2013 9:21:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; ALK (OMX: ALK.B) announces positive outcome of the second of two pivotal Phase III trials of its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. The MITRA[1] trial meets its primary endpoint and demonstrates a significant reduction in the risk of moderate-to-severe asthma exacerbations.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES